APP and Alzheimer disease: Of note, in a transgenic AD mouse model, a-30 day transcranial PBM treatment (632.8 nm, continuous wave, 2 J/cm2 at the hippocampus level daily) shifted APP processing toward the nonamyloidogenic pathway [51].